Wellington Management Group LLP Has $4.75 Million Holdings in Enfusion, Inc. (NYSE:ENFN)

Wellington Management Group LLP raised its position in shares of Enfusion, Inc. (NYSE:ENFN) by 5.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 489,364 shares of the company’s stock after buying an additional 26,464 shares during the period. Wellington Management Group LLP owned about 0.38% of Enfusion worth $4,747,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its position in shares of Enfusion by 680.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,894 shares of the company’s stock worth $96,000 after purchasing an additional 8,627 shares during the last quarter. Barclays PLC grew its position in shares of Enfusion by 29.0% during the 3rd quarter. Barclays PLC now owns 10,809 shares of the company’s stock worth $96,000 after buying an additional 2,430 shares during the period. Azora Capital LP acquired a new position in shares of Enfusion during the 4th quarter worth about $134,000. Algert Global LLC bought a new stake in shares of Enfusion in the 3rd quarter valued at about $139,000. Finally, Swiss National Bank raised its position in shares of Enfusion by 55.7% in the 3rd quarter. Swiss National Bank now owns 49,500 shares of the company’s stock valued at $444,000 after acquiring an additional 17,700 shares during the period. Institutional investors own 81.05% of the company’s stock.

Enfusion Trading Down 0.8 %

Shares of NYSE ENFN opened at $8.52 on Friday. The company has a fifty day moving average price of $9.07 and a 200 day moving average price of $9.06. The firm has a market cap of $1.09 billion, a PE ratio of 284.09, a PEG ratio of 2.00 and a beta of 0.96. Enfusion, Inc. has a 1-year low of $7.52 and a 1-year high of $11.56.

Enfusion (NYSE:ENFN) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.05). The firm had revenue of $48.05 million for the quarter, compared to analyst estimates of $47.67 million. Enfusion had a return on equity of 6.60% and a net margin of 1.40%. During the same period in the prior year, the company earned $0.04 earnings per share. Equities research analysts forecast that Enfusion, Inc. will post 0.09 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on ENFN. Bank of America upped their target price on shares of Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research note on Wednesday, March 13th. Morgan Stanley began coverage on Enfusion in a research note on Friday, May 10th. They set an “overweight” rating and a $11.00 price objective on the stock. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $9.33.

Insider Transactions at Enfusion

In related news, Director Deirdre Somers sold 4,629 shares of the firm’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $8.40, for a total value of $38,883.60. Following the completion of the transaction, the director now owns 43,312 shares of the company’s stock, valued at $363,820.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Enfusion news, Director Deirdre Somers sold 4,629 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $8.40, for a total value of $38,883.60. Following the completion of the transaction, the director now directly owns 43,312 shares in the company, valued at $363,820.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Bronwen Bastone sold 18,241 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $8.11, for a total value of $147,934.51. Following the sale, the insider now owns 198,913 shares in the company, valued at approximately $1,613,184.43. The disclosure for this sale can be found here. Insiders have sold a total of 36,318 shares of company stock valued at $296,688 over the last 90 days. 36.44% of the stock is owned by corporate insiders.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.